Latest Doxorubicin Stories
LAGUNA HILLS, Calif., Feb.
MADRID, February 3, 2015 /PRNewswire/ -- PharmaMar announces that the U.S.
RARITAN, N.J., Feb. 3, 2015 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S.
BIRMINGHAM, Ala., Jan.
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
Company does not expect estimated timelines to materially change LOS ANGELES, Jan.
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients LOS ANGELES, Jan.
QUÉBEC CITY, Dec. 29, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
Company Continues to Expect Clinical Trial Timelines to Remain Materially Unchanged and Expeditiously Resolved LOS ANGELES, Dec.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.